1. Home
  2. NHI vs NAMS Comparison

NHI vs NAMS Comparison

Compare NHI & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National Health Investors Inc.

NHI

National Health Investors Inc.

HOLD

Current Price

$76.00

Market Cap

3.8B

Sector

Real Estate

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$34.06

Market Cap

4.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NHI
NAMS
Founded
1991
2019
Country
United States
Netherlands
Employees
N/A
100
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
4.1B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
NHI
NAMS
Price
$76.00
$34.06
Analyst Decision
Buy
Strong Buy
Analyst Count
5
8
Target Price
$87.00
$46.75
AVG Volume (30 Days)
922.5K
1.1M
Earning Date
05-04-2026
05-06-2026
Dividend Yield
4.81%
N/A
EPS Growth
N/A
N/A
EPS
0.82
N/A
Revenue
$375,628,000.00
N/A
Revenue This Year
$15.44
$17.96
Revenue Next Year
$10.01
$540.65
P/E Ratio
$94.50
N/A
Revenue Growth
12.07
N/A
52 Week Low
$67.94
$20.53
52 Week High
$91.38
$42.21

Technical Indicators

Market Signals
Indicator
NHI
NAMS
Relative Strength Index (RSI) 55.38 59.57
Support Level $75.34 $33.83
Resistance Level $77.84 $37.27
Average True Range (ATR) 1.61 1.59
MACD 0.64 0.53
Stochastic Oscillator 75.74 75.57

Price Performance

Historical Comparison
NHI
NAMS

About NHI National Health Investors Inc.

National Health Investors Inc is a self-managed REIT that owns, leases, operates, and finances the development of senior housing communities and medical facilities. It operates through two segments: Real Estate Investments and Senior Housing Operating Portfolio (SHOP). The Real Estate Investments segment, which generates the majority of revenue, includes real estate leases, mortgages, and other notes receivable related to independent living facilities, assisted living facilities, entrance fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment consists of ventures that own and operate independent living facilities. The company's revenues are derived from rental income, interest and other income, and resident fees and services.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: